JAKAFI Drug Patent Profile

Which patents cover Jakafi, and what generic alternatives are available?

Jakafi is a drug marketed by Incyte Corp and is included in one NDA. There are eight patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and thirty-six patent family members in forty-six countries.

The generic ingredient in JAKAFI is ruxolitinib phosphate. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ruxolitinib phosphate profile page.

DrugPatentWatch^® Generic Entry Outlook for Jakafi

Jakafi was eligible for patent challenges on November 16, 2015.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 12, 2028. This may change due to patent challenges or generic licensing.

There have been four patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for JAKAFI

International Patents:	236
US Patents:	8
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for JAKAFI

Paragraph IV (Patent) Challenges for JAKAFI

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
JAKAFI	Tablets	ruxolitinib phosphate	5 mg, 10 mg, 15 mg, 20 mg, and 25 mg	202192	1	2015-12-17

US Patents and Regulatory Information for JAKAFI

JAKAFI is protected by eight US patents and six FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 8,722,693.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Incyte Corp	JAKAFI	ruxolitinib phosphate	TABLET;ORAL	202192-003	Nov 16, 2011		RX	Yes	No
Incyte Corp	JAKAFI	ruxolitinib phosphate	TABLET;ORAL	202192-003	Nov 16, 2011		RX	Yes	No	8,822,481*PED				Y
Incyte Corp	JAKAFI	ruxolitinib phosphate	TABLET;ORAL	202192-004	Nov 16, 2011		RX	Yes	No	10,016,429*PED				Y
Incyte Corp	JAKAFI	ruxolitinib phosphate	TABLET;ORAL	202192-005	Nov 16, 2011		RX	Yes	Yes	8,822,481*PED				Y
Incyte Corp	JAKAFI	ruxolitinib phosphate	TABLET;ORAL	202192-004	Nov 16, 2011		RX	Yes	No	8,722,693*PED				Y
Incyte Corp	JAKAFI	ruxolitinib phosphate	TABLET;ORAL	202192-004	Nov 16, 2011		RX	Yes	No	9,814,722*PED				Y
Incyte Corp	JAKAFI	ruxolitinib phosphate	TABLET;ORAL	202192-004	Nov 16, 2011		RX	Yes	No

International Patents for JAKAFI

When does loss-of-exclusivity occur for JAKAFI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Colombia

Costa Rica

Croatia

Cuba

Cyprus

Denmark

Dominican Republic

Ecuador

Eurasian Patent Organization

European Patent Office

Georgia, Republic of

Guatemala

Hong Kong

Hungary

Israel

Japan

Lithuania

Malaysia

Mexico

Montenegro

Morocco

New Zealand

Nicaragua

Norway

Poland

Portugal

San Marino

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Tunisia

Turkey

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering JAKAFI around the world.

Country	Patent Number	Title	Estimated Expiration
Ecuador	SP12008540
Spain	2970354
Cyprus	1118607
Slovenia	2343299
Serbia	55576
Brazil	PI0814254	SAIS DO INIBIDOR DE JANUS QUINASE(R)-3(-4(7H-PIRROLO[2,3-D]PIRIMIDIN-4-IL)-1H-PIRAZ OL-1-IL)-3-CICLOPENTILPROPANONITRILA
European Patent Office	3466953	DÉRIVÉ DE PYRROLO[2,3-B]PYRIMIDINE EN TANT QU'INHIBITEUR DE JANUS KINASE (PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE AS JANUS KINASE INHIBITOR)

Supplementary Protection Certificates for JAKAFI

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1966202	145 1-2013	Slovakia		FORMER OWNER: INCYTE CORPORATION, WILMINGTON, DE, US;
1966202	CA 2013 00005	Denmark
1966202	C 2013 005	Romania		PRODUCT NAME: RUXOLITINIB SAU O SARE FARMACEUTIC ACCEPTABILA AACESTUIA; NATIONAL AUTHORISATION NUMBER: RO EU/1/12/773/001, RO EU/1/12/773/002, RO EU/1/12/773/003; DATE OF NATIONAL AUTHORISATION: 20120823; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EMEA EU/1/12/773/001, EMEA EU/1/12/773/002, EMEA EU/1/12/773/003; DATE OF FIRST AUTHORISATION IN EEA: 20120823
2455382	CA 2017 00018	Denmark		PRODUCT NAME: RUXOLITINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER RUXOLITINIB FOSFAT; REG. NO/DATE: C(2015)1740/EU/1/12/773/001-016 20150313
2455382	122017000020	Germany		PRODUCT NAME: RUXOLITINIB, ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON; REGISTRATION NO/DATE: EU/1/12/773/001-003 20150311
1966202	C300574	Netherlands		PRODUCT NAME: RUXOLITINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/12/773/001-003 20120823
2455382	300870	Netherlands		PRODUCT NAME: RUXOLITINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/12/773/001-016 20150313

JAKAFI (ruxolitinib): Investment scenario and fundamentals analysis

Last updated: April 24, 2026

What is JAKAFI and how is it positioned commercially?

JAKAFI is brand ruxolitinib, an oral Janus kinase (JAK) inhibitor. It is the primary revenue driver for Incyte’s marketed franchise in myelofibrosis (MF) and has a material presence in other approved inflammatory and hematologic indications. The investment thesis typically hinges on (1) durability of MF demand and pricing, (2) label and formulation expansion (including topical or combination strategies where applicable), (3) competitive erosion from other JAK inhibitors and pipeline entrants, and (4) biosimilar and small-molecule competitive pressures tied to patent life and generic timing.

Core market exposure (indication-level drivers)

• Myelofibrosis (primary commercial base): JAKAFI is a standard-of-care option in multiple MF subtypes and treatment settings where efficacy and symptom control are key endpoints.
• Polycythemia vera and steroid-refractory/relapsed disease settings (where applicable by label and region): ruxolitinib addresses disease control and symptom burden, supporting ongoing prescription and persistence.
• Other JAK inhibitor competitors: the therapeutic class includes multiple marketed agents competing on overall symptom response, transfusion independence, and survival-related endpoints, depending on setting.

Revenue and growth are ultimately driven by

• patient incidence and diagnosis rates,
• line-of-therapy migration,
• dosing persistence (discontinuation and dose reductions),
• payer reimbursement dynamics,
• and share capture from competitors and/or share loss to alternative JAK pathways.

What are the fundamentals that matter for investors?

Fundamentals analysis for JAKAFI focuses on cash-generation stability, market access, and the durability of exclusivity.

1) Supply, formulation, and manufacturing

• JAKAFI is an oral small molecule with established commercial manufacturing.
• Operational resilience tends to protect revenue during demand swings, new-winner competition, and formulary tiering changes.
• For investors, manufacturing continuity usually matters more during product transitions and supply constraints than for routine forecasting because the molecule is not a biologic with cold-chain or batch heterogeneity risk.

2) Demand durability in myelofibrosis

• MF is the anchor indication; the main fundamental is whether ruxolitinib maintains durable prescription volume under competitive pressure and shifting guideline preferences.
• The durable driver is patient selection: ruxolitinib’s clinical positioning generally targets symptom control and hematologic improvements, which influence payer approvals and physician adherence.

3) Pricing and payer access

JAK inhibitors face class-wide payer scrutiny. Investors should evaluate:

• formulary placement and prior authorization intensity,
• step therapy and switching rules,
• net price trends versus list price,
• and regional reimbursement volatility.

4) Competitive landscape within JAK class

• Competitors in MF can shift market share if they demonstrate superior endpoints in the same payer decision window, or if they secure preferential formulary placement.
• Competitive switching is sensitive to incremental clinical benefit as measured in real-world practice and to route-to-coverage (time to approval, documentation burden, and restrictions by lab metrics).

What is the investment scenario: upside, base case, and downside?

The investment scenario for JAKAFI is best framed around three interacting variables: (1) MF market retention, (2) competitive share, and (3) exclusivity and patent risk (generic or authorized generic entry timing).

Upside scenario (share-stable with label and market-access tailwinds)

• JAKAFI sustains prescription volume in MF by retaining a larger share of first-line and second-line treated patients than competitors.
• Net pricing holds due to continued strong formulary positioning and consistent payer support for symptom and disease control endpoints.
• The company captures incremental momentum from guideline adherence and expanding physician confidence in long-term tolerability.

Catalyst profile

• Positive incremental safety/tolerability signals in routine use
• Further label clarity that increases eligible patient pools in key geographies
• Market-access improvements that reduce time-to-therapy

Base case (moderate share pressure, stable demand)

• Competitive pressure trims share in parts of MF, with growth flattening into a maturity curve.
• Pricing remains stable-to-soft as payer negotiations normalize.
• R&D spend remains disciplined while maintaining support for line extensions and post-marketing evidence generation.

What holds the base case together

• MF treatment inertia
• patient persistence driven by symptom control
• incremental real-world adoption where clinical benefit aligns with payer policy

Downside scenario (share erosion plus price pressure ahead of exclusivity changes)

• Competitors take formulary share through aggressive contracting and product positioning in MF.
• Payer restrictions tighten, increasing the share of later-line usage with lower persistence.
• Exclusivity risk leads to accelerated discounting and earlier-than-expected erosion in net price.

What breaks revenue

• A step-change in payer coverage rules
• broad prescribing displacement from MF specialists to alternative JAK inhibitors
• any earlier-than-modeled generic entry dynamics

What is the patent and exclusivity landscape investors should model?

For JAKAFI, the investor-relevant patent question is not “does it have patents,” but “what is the practical time path for generic erosion in each major market,” which depends on:

• primary composition of matter coverage,
• specific method-of-use protection,
• and jurisdictional enforcement outcomes.

Key practical elements to incorporate into models:

• Country-by-country exclusivity: generic entry risk can differ by jurisdiction.
• Secondary patent claims: method-of-use and specific dosing schedules can delay generic launches in particular labels.
• Litigation timelines: settlement and injunction outcomes can reshape effective exclusivity.

How should an investor underwrite JAKAFI cash flows?

A cash-flow underwrite for ruxolitinib should be driven by a unit-and-net-price bridge rather than headline growth.

Step 1: Volume model built on treated-patient persistence

Use treated-patient logic for MF:

• estimate incident and diagnosed MF populations,
• share of treated patients,
• line-of-therapy distribution,
• average duration of therapy (persistence curve),
• and discontinuation drivers (toxicity, efficacy plateau, switch rates).

Step 2: Net price model

Build net price as:

• list price minus rebates/discounts,
• adjusted for payer mix and geographies,
• plus expected changes tied to formulary status and contracting cycles.

Step 3: Competitive share shifts

Apply scenario-based share change:

• stable share in upside,
• incremental share loss in base case,
• larger share loss in downside, aligned with payer contracting and guideline shifts.

Step 4: Exclusivity and launch calendar

Map generic risk windows by major markets:

• use effective exclusivity end dates,
• add litigation-driven “optionality” for settlements and launch delays,
• and model “speed of erosion” in early months after launch.

What are the key operational and regulatory risks?

Regulatory

• Label changes tied to safety findings can alter eligibility pools and payer approvals.
• Post-marketing requirements and risk management programs can affect prescribing behavior.

Operational

• Supply continuity matters for oral drugs during peak demand and when manufacturing capacity is constrained.
• Quality system issues can cause temporary disruptions and downstream inventory effects for wholesalers.

Commercial

• Formulary exclusions and tightened prior authorization accelerate discontinuation or delay initiation.
• Switching is often driven by real-world criteria such as transfusion independence and symptom scales that map to payer policy.

How does JAKAFI fit versus the broader hematology portfolio risk profile?

JAKAFI behaves like a mature specialty franchise:

• The upside is driven by patient persistence and share capture.
• The downside is driven by pricing pressure and effective exclusivity erosion.

This profile is typically less volatile than early-stage assets, but it becomes sensitive to:

• market-access changes,
• competitive contract dynamics,
• and patent enforcement outcomes that can shift launch timing.

What should investors monitor each quarter?

Investors should monitor a small set of leading indicators tied to share, net price, and persistence:

• trends in MF prescription volume and treated patients,
• net price metrics and payer contracting commentary,
• inventory and channel fill changes,
• and any guidance revisions tied to market access or competitive dynamics.

Key Takeaways

• JAKAFI is an established ruxolitinib franchise with its fundamentals anchored in myelofibrosis patient persistence and market access.
• The investment scenario is primarily a model of volume persistence, net price durability, and competitive share trajectory under payer contracting pressure.
• The decisive longer-term variable is effective exclusivity by jurisdiction, which determines the speed and timing of generic erosion.
• Near-term financial outcomes are most sensitive to (1) treated-patient persistence and (2) net price trends rather than headline growth.
• Quarterly monitoring should focus on volume indicators tied to MF demand and pricing metrics tied to payer access.

FAQs

1) What is JAKAFI’s main commercial indication?

JAKAFI’s principal revenue base is myelofibrosis, where ruxolitinib is used to manage disease and symptom burden across labeled settings.

2) What drives JAKAFI net sales most: volume or pricing?

For mature specialty brands like JAKAFI, both matter; net sales usually track treated-patient persistence and net price under payer contracting more than short-lived marketing changes.

3) How do competitive JAK inhibitors typically affect JAKAFI?

They shift share through formulary contracting, clinical differentiation in relevant endpoints, and payer policies that influence eligibility and switching.

4) What is the biggest investor modeling risk for JAKAFI?

The biggest risk is mis-timing effective exclusivity and underestimating post-launch pricing erosion if generic entry occurs earlier or erodes faster than modeled.

5) What quarterly signals indicate whether the bull or bear scenario is playing out?

Bull signals are stable-to-improving treated-patient persistence and pricing durability. Bear signals are accelerating net price declines, weakening prescription volumes in MF, and increased payer restrictions.

---

References

[1] Incyte Corporation. “JAKAFI (ruxolitinib) Prescribing Information.” U.S. FDA.
[2] U.S. Food and Drug Administration. “JAKAFI (ruxolitinib) Label Information.” FDA.
[3] Drugs@FDA. “JAKAFI (ruxolitinib) Approval History and Label.” FDA.
[4] National Comprehensive Cancer Network (NCCN). “Myelofibrosis Guidelines (JAK inhibitor use).” NCCN.